Faron Pharmaceuticals OY (FARN) NPV

Sell:160.00pBuy:162.00p1.00p (0.62%)

FTSE AIM 100:0.93%
Market closed | Prices delayed by at least 15 minutes
Sell:160.00p
Buy:162.00p
Change:1.00p (0.62%)
Market closed | Prices delayed by at least 15 minutes
Sell:160.00p
Buy:162.00p
Change:1.00p (0.62%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.

Key people

Juho Markku Jalkanen
Chief Executive Officer
Yrjo Erik Krist Wichmann
Chief Financial Officer
Maija Hollmen
Chief Scientific Officer
Markku Jalkanen
Executive Director
Petri Bono
Chief Medical Officer
Tuomo Tapani Paetsi
Non-Executive Chairman of the Board
Marie-Louise Helena Fjallskog
Non-Executive Director
Christine Ann Roth
Non-Executive Director
John Poulos
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    FARN
  • Location
    Finland
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    FI4000153309
  • Market cap
    £179.68m
  • Employees
    34
  • Shares in issue
    104.62m
  • Exchange
    London Stock Exchange (LON)
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.